Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2024-12-17 00:00:00 ET · period of report 2024-12-13 · accession 0000935836-24-000763 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-12-17 | 2024-12-17 | OLMA | Graham G. Walmsley | Dir | P - Purchase | $6.75 | -700.8K | 1.41M | -33% | -$4.73M |
| I | 2024-12-17 | 2024-12-17 | OLMA | Graham G. Walmsley | Dir | S - Sale | $6.75 | -700.8K | 0 | -100% | -$4.73M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-17 | P | D | 700,761 | $6.75 | 1,408,875 | I See note | — | — | (F2) The shares are held by Logos Opportunities Fund IV LP ("Logos Fund IV"). Logos Opportunities IV GP LLC ("GP IV") is the general partner of Logos Fund IV and the reporting person is a managing member of GP IV. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
| 2 | Common | Common Stock | 2024-12-17 | S | D | 700,761 | $6.75 | 0 | I See note | — | — | (F1) The shares are held by Logos Opportunities Fund I LP ("Logos Fund I"). Logos Opportunities GP, LLC ("Logos Opportunities GP") is the general partner of Logos Fund I and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |